{"id":2072,"date":"2004-04-01T12:07:00","date_gmt":"2004-04-01T10:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/vorbehandlung-mit-clopidogrel-macht-abciximab-wirkungslos"},"modified":"2004-04-01T12:07:00","modified_gmt":"2004-04-01T10:07:00","slug":"vorbehandlung-mit-clopidogrel-macht-abciximab-wirkungslos","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/vorbehandlung-mit-clopidogrel-macht-abciximab-wirkungslos","title":{"rendered":"Vorbehandlung mit Clopidogrel macht Abciximab wirkungslos"},"content":{"rendered":"<p>Die periinterventionelle Gabe von GP-IIb\/IIIa-Rezeptor-Antagonisten (GP-RA: Abciximab = ReoPro\u00ae, Tirofiban = Aggrastat\u00ae, Eptifibatid = Integrilin\u00ae) hat die Koronarintervention bei akuten Koronarsyndromen durch Verminderung thrombotischer Komplikationen sicherer gemacht (s.a. 1, 2). Die mindestens einmonatige Gabe von ADP-Rezeptorantagonisten (ADP-RA: Ticlopidin, Clopidogrel = Iscover\u00ae, Plavix\u00ae) vermindert nach einer Stent-Implantation die H\u00e4ufigkeit von Stent-Thrombosen und Restenosen (s.a. 3, 4). [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die periinterventionelle Gabe von GP-IIb\/IIIa-Rezeptor-Antagonisten (GP-RA: Abciximab = ReoPro\u00ae, Tirofiban = Aggrastat\u00ae, Eptifibatid = Integrilin\u00ae) hat die Koronarintervention bei akuten Koronarsyndromen durch Verminderung thrombotischer Komplikationen sicherer gemacht (s.a. 1, 2). Die mindestens einmonatige Gabe von ADP-Rezeptorantagonisten (ADP-RA: Ticlopidin, Clopidogrel = Iscover\u00ae, Plavix\u00ae) vermindert nach einer Stent-Implantation die H\u00e4ufigkeit von Stent-Thrombosen und Restenosen (s.a. 3, 4). [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1464,73,730,729,4257,727],"class_list":["post-2072","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abciximab","tag-clopidogrel","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-isar-react-studie","tag-thrombozytenaggregationshemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2072"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2072\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}